B. Crestani (Paris, France), A. Prasse (Hannover, Germany)
LSC - 2019 - Inflammasomes’ activation in alveolar macrophages and peripheral blood mononuclear cells in fibrotic Interstitial Lung Diseases
A. Trachalaki (Herakleion, Greece), E. Tsitoura (Herakleion, Greece), E. Vasarmidi (Herakleion, Greece), E. Bibaki (Herakleion, Greece), N. Tzanakis (Herakleion, Greece), K. Antoniou (Herakleion, Greece)
|  |
Potential clinical utility of MUC5B and TOLLIP single nucleotide polymorphisms (SNP) in in the management of patients with IPF.
F. Bonella (Essen, Germany), I. Campo (Pavia, Italy), E. Boerner (Essen, Germany), D. Theegarten (Essen, Germany), J. Guzman (Bochum, Germany), U. Costabel (Essen, Germany)
| |
Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice
K. Kagawa (Tokushima, Japan), K. Koyama (Tokushima, Japan), S. Sato (Tokushima, Japan), N. Takahashi (Tokushima, Japan), H. Nishimura (Tokushima, Japan), N. Naito (Tokushima, Japan), H. Kawano (Tokushima, Japan), Y. Toyoda (Tokushima, Japan), Y. Nishioka (Tokushima, Japan)
| |
Arsenic trioxyde inhibits the functions on lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
A. Joannes (RENNES, France), C. Morzadec (RENNES, France), M. Duclos (RENNES, France), N. Bellamri (RENNES, France), F. Llamas Gutierrez (RENNES, France), B. Richard De Latour (RENNES, France), S. Wollin (Biberach an der Riss, Germany), S. Jouneau (RENNES, France), L. Vernhet (RENNES, France)
| |
IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF
K. Kossen (Cambridge, United States of America), C. Schaefer (Cambridge, United States of America), S. Lim (Cambridge, United States of America), M. Michener (Cambridge, United States of America), P. Ruminiski (Cambridge, United States of America), D. Griggs (Cambridge, United States of America), R. Radhakrishnan (Cambridge, United States of America), B. Bradford (Cambridge, United States of America), S. Seiwert (Cambridge, United States of America)
| |
The effect of mast cell stabilisation in a large animal model of pulmonary fibrosis
S. Vithana Dewage (Melbourne, Australia), A. Stent (Werribee, Australia), H. Derseh (Melbourne, Australia), K. Perera (Melbourne, Australia), L. Organ (Nottingham, United Kingdom), K. Snibson (melbourne, Australia)
|  |
Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis
K. Roach (Leicester, United Kingdom), E. Castells (Leicester, United Kingdom), P. Tongue (Leicester, United Kingdom), G. Elliott (Leicester, United Kingdom), H. Marshall (Leicester, United Kingdom), M. Richardson (Leicester, United Kingdom), L. Chachi (Leicester, United Kingdom), S. Mason (Leicester, United Kingdom), A. Sutcliffe (Leicester, United Kingdom), P. Bradding (Leicester, United Kingdom)
| |
Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model
X. Li (Tianjin, China), Z. Lv (Tianjin, China), K. Huang (Tianjin, China), W. Gan (Tianjin, China), S. Gao (Tianjin, China), B. Yang (Tianjin, China), K. Helian (Tianjin, China), H. Zhou (Tianjin, China)
| |
TGFß1-induces resistance to apoptosis in human lung myofibroblasts via TRPA1 downregulation
H. Virk (Leicester, United Kingdom), J. Mccarthy (Leicester, United Kingdom), E. Castells (Leicester, United Kingdom), C. Feghali-Bostwick (Charleston, United States of America), V. Bowman (Leicester, United Kingdom), Y. Amrani (Leicester, United Kingdom), D. Cousins (Leicester, United Kingdom), P. Bradding (Leicester, United Kingdom), K. Roach (Leicester, United Kingdom)
| |
Autophagy and senescence are activated mechanisms in idiopathic or autoimmunity caused usual interstitial pneumonia
H. Popper (Graz, Austria), E. Stacher-Priehse (Gauting, Germany), L. Brcic (Graz, Austria), S. Eidsenhammer (Graz, Austria), F. Gallob (Graz, Austria), F. Rampp (Munich, Germany), A. Nerlich (Munich, Germany)
| |
Oleanolic acid acetate ameliorates bleomycin-induced pulmonary fibrosis through inhibition of epithelial-mesenchymal transition
H. Kim (Iksan, Republic of Korea), K. Hwang (Iksan, Republic of Korea), C. Park (Iksan, Republic of Korea), J. Jung (Iksan, Republic of Korea), E. Jeong (Iksan, Republic of Korea)
| |
Defective surfactant biosynthesis and ultrastructural abnormalities of alveolar type 2 cells in pulmonary fibrosis of conditional Nedd4-2mice
D. Leitz (Heidelberg, Germany), J. Duerr (Berlin, Germany), J. Hegermann (Hannover, Germany), L. Knudsen (Hannover, Germany), S. Mulugeta (Philadelphia, United States of America), M. Ochs (Hannover, Germany), M. Beers (Philadelphia, United States of America), M. Mall (Berlin, Germany)
| |
Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis.
N. Chandran (Graz, Austria), N. Sharma (Graz, Austria), L. Wollin (Biberach, Germany), A. Olschewski (Graz, Austria), G. Kwapiszewska (Graz, Austria), H. Olschewski (Graz, Austria)
| |
LPA1 antagonist BMS-986278 for idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation
B. Murphy (Princeton, United States of America), C. Sum (Princeton, United States of America), T. Wang (Princeton, United States of America), R. Heiry (Princeton, United States of America), S. Kalinowski (Princeton, United States of America), C. Hung (Princeton, United States of America), C. Chu (Princeton, United States of America), A. Azzara (Princeton, United States of America), Z. Milinda (Princeton, United States of America), L. Burns (Princeton, United States of America), B. Zinker (Princeton, United States of America), S. Boehm (Princeton, United States of America), J. Taylor (Princeton, United States of America), J. Sapuppo (Princeton, United States of America), M. Kathy (Princeton, United States of America), C. Mary-Ellen (Princeton, United States of America), R. Kaltenbach (Princeton, United States of America), S. Dhanusu (Princeton, United States of America), S. Tao (Princeton, United States of America), H. Zhang (Princeton, United States of America), L. Kennedy (Princeton, United States of America), J. Shi (Princeton, United States of America), J. Li (Princeton, United States of America), S. Walker (Princeton, United States of America), Y. Shi (Princeton, United States of America), Y. Wang (Princeton, United States of America), R. Reddigunta (Princeton, United States of America), R. Jeffrey (Princeton, United States of America), B. Ellsworth (Princeton, United States of America), D. Gordon (Princeton, United States of America), M. Soars (Princeton, United States of America), M. Gill (Princeton, United States of America), P. Cheng (Princeton, United States of America)
| |
Role of MUC4 in idiopathic pulmonary fibrosis
B. Ballester Llobell (VALENCIA, Spain), J. Milara Payá (VALENCIA, Spain), P. Montero Magalló (VALENCIA, Spain), I. Roger Laparra (Madrid, Spain), C. Estornut Navarro (VALENCIA, Spain), J. Cortijo Gimeno (VALENCIA, Spain)
| |
In vivo blockade of KCa3.1 ion channel alleviates ER stress in type II alveolar epithelial cells and macrophages in pulmonary fibrosis
K. Perera (Melbourne, Australia), S. Vithana Dewage (Melbourne, Australia), H. Derseh (Melbourne, Australia), P. Benham (Melbourne, Australia), A. Stent (Melbourne, Australia), L. Organ (Nottingham, United Kingdom), K. Snibson (Melbourne, Australia)
| |
Tankyrase(TNKS) inhibiting autophagy promotes the TGF-ß induced EMT process in vitro and Bleomycin(BLM) induced pulmonary fibrosis in rats
L. Liu (Chengdu, China), T. Wang (Chengdu, China), Z. Yuan (Chengdu, China), D. Xu (Chengdu, China), F. Wen (Chengdu, China)
| |